Full Press Release Details
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer.
IMMP
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Key Takeaway: Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Price reaction · baseline $1.54 (2023-05-15 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close
+3.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)